Last reviewed · How we verify
NCT07093073
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Phase 1 trial testing ssCART-19 in B Cell Lymphoma in 30 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 January 2025 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2029 |
| Sites | 3 locations across China |
Drugs / interventions tested
- ssCART-19 — full drug profile →
Conditions studied
- B Cell Lymphoma — all drugs for B Cell Lymphoma →
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd — full company profile →
Who can join
Adults 2 to 75, any sex, with B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07093073
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ssCART-19
Trials testing the same drug.
- NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
Other recruiting trials for B Cell Lymphoma
Currently open trials in the same condition.
- NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06976437 — A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
- NCT06742996 — A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Phase 3 · recruiting
Other Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd trials
Trials by the same sponsor.
- NCT07036250 — Clinical Study of U32 in Patients With Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT07453446 — Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma · Phase 1 · recruiting
- NCT07093086 — Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma · Phase 1 · recruiting
- NCT06614686 — U87 CAR-T in Patients With Advanced Head and Neck Tumors · Phase 1 · recruiting
- NCT05768529 — Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07093073 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07093073.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing